New CEO commentary: “The Single-Cell Revolution”

On the company’s webpage, PHI’s CEO and founder Peter Egelberg comments the recently published innovation report from the UN agency World Intellectual Property Organization. The report sets PHI’s technology area, single-cell analysis, as the cutting-edge technology that is most likely to revolutionize healthcare over the next decade — outranking high-profile innovations such as regenerative medicine, immunotherapy and gene therapy, see phiab.com/commentary/the-single-cell-analysis-revolution.